Absorption, Distribution, Metabolism, and Excretion of [14C]BS1801, a Selenium-Containing Drug Candidate, in Rats
Molecules · 2023
DOI: 10.3390/molecules28248102 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2023. Verfasst von Cheng Yang und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China. Hauptthemen laut MEDLINE: Selenium. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, the National Key R&D Program of China, Key Technologies R&D Program of Guangdong Province.
Abstract (Originalsprache)
BS1801 is a selenium-containing drug candidate with potential for treating liver and lung fibrosis. To fully elucidate the biotransformation of BS1801 in animals and provide sufficient preclinical drug metabolism data for human mass balance study, the metabolism of BS1801 in rats was investigated. We used radiolabeling techniques to investigate the mass balance, tissue distribution, and metabolite identification of BS1801 in Sprague–Dawley/Long–Evans rats after a single oral dose of 100 mg/kg (100 μCi/kg) [14C]BS1801: 1. The mean recovery of radioactive substances in urine and feces was 93.39% within 168 h postdose, and feces were the main excretion route. 2. Additionally, less than 1.00% of the dose was recovered from either urine or bile. 3. BS1801-related components were widely distributed throughout the body. 4. Fifteen metabolites were identified in rat plasma, urine, feces, and bile, and BS1801 was detected only in feces. 5. BS1801-M484, the methylation product obtained via a N–Se bond reduction in BS1801, was the most abundant drug-related component in plasma. The main metabolic pathways of BS1801 were reduction, amide hydrolysis, oxidation, and methylation. Overall, BS1801 was distributed throughout the body, and excreted mainly as an intact BS1801 form through feces. No differences were observed between male and female rats in distribution, metabolism, and excretion of BS1801.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China.
- Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201210, China.
- Jiangsu Key Laboratory for Functional Substances of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China.
- Shanghai Yuanxi Pharmaceutical Technology Co., Ltd., Shanghai 201203, China.
ORCID-Profile: Xingxing Diao
Förderung
- National Natural Science Foundation of China
- the National Key R&D Program of China
- Key Technologies R&D Program of Guangdong Province
- Shanghai Yuanxi Medicine Corp
- the National Key R&D Program of China
- Key Technologies R&D Program of Guangdong Province
Zitieren
APA
Yang, C., Xue, M., He, Y., Yin, H., Yang, C., Zhong, D., Zeng, H., Zheng, Y., & Diao, X. (2023). Absorption, Distribution, Metabolism, and Excretion of [14C]BS1801, a Selenium-Containing Drug Candidate, in Rats. Molecules. https://doi.org/10.3390/molecules28248102
Vancouver
Yang C, Xue M, He Y, Yin H, Yang C, Zhong D, et al. Absorption, Distribution, Metabolism, and Excretion of [14C]BS1801, a Selenium-Containing Drug Candidate, in Rats. Molecules. 2023. doi:10.3390/molecules28248102
BibTeX
@article{Yang2023,
author = {Yang, Cheng and Xue, Mingzhen and He, Yifei and Yin, Hanwei and Yang, Chen and Zhong, Dafang and Zeng, Huihui and Zheng, Yuandong and Diao, Xingxing},
title = {Absorption, Distribution, Metabolism, and Excretion of [14C]BS1801, a Selenium-Containing Drug Candidate, in Rats},
journal = {Molecules},
year = {2023},
doi = {10.3390/molecules28248102}
}
EUVIMED